Analgesics..
Antiandrogens..
Bromhexine
Budesonide
Cannabidiol
Colchicine
Conv. Plasma
Curcumin
Ensovibep
Famotidine
Favipiravir
Fluvoxamine
Hydroxychlor..
Iota-carragee..
Ivermectin
Lactoferrin
Lifestyle..
Melatonin
Metformin
Molnupiravir
Monoclonals..
Nigella Sativa
Nitazoxanide
Nitric Oxide
Paxlovid
Peg.. Lambda
Povidone-Iod..
Quercetin
Remdesivir
Vitamins..
Zinc

Other
Feedback
Home
Home   COVID-19 treatment studies for Molnupiravir  COVID-19 treatment studies for Molnupiravir  C19 studies: Molnupiravir  Molnupiravir   Select treatmentSelect treatmentTreatmentsTreatments
Melatonin Meta
Bromhexine Meta Metformin Meta
Budesonide Meta Molnupiravir Meta
Cannabidiol Meta
Colchicine Meta Nigella Sativa Meta
Conv. Plasma Meta Nitazoxanide Meta
Curcumin Meta Nitric Oxide Meta
Ensovibep Meta Paxlovid Meta
Famotidine Meta Peg.. Lambda Meta
Favipiravir Meta Povidone-Iod.. Meta
Fluvoxamine Meta Quercetin Meta
Hydroxychlor.. Meta Remdesivir Meta
Iota-carragee.. Meta
Ivermectin Meta Zinc Meta
Lactoferrin Meta

Other Treatments Global Adoption
All Studies   All Outcomes   Recent: 
0 0.5 1 1.5 2+ Death/hospitalization, d.. -100% Improvement Relative Risk Death/hospitalizatio.. (b) -85% c19early.org/m Zheng et al. Molnupiravir for COVID-19 EARLY TREATMENT Favors molnupiravir Favors sotrovimab
Comparative effectiveness of sotrovimab and molnupiravir for prevention of severe covid-19 outcomes in patients in the community: observational cohort study with the OpenSAFELY platform
Zheng et al., BMJ, doi:10.1136/bmj-2022-071932
16 Nov 2022    Source   PDF   Share   Tweet
Retrospective 3,331 sotrovimab and 2,689 molnupiravir patients in the UK, showing higher risk of combined hospitalization/death with molnupiravir.
Concerns have been raised that the mutagenic mechanism of action may create dangerous variants or cause cancer [Hadj Hassine, Swanstrom].
risk of death/hospitalization, 100% higher, HR 2.00, p = 0.005, treatment 61 of 2,689 (2.3%), control 34 of 3,331 (1.0%), adjusted per study, inverted to make HR<1 favor treatment, multivariable, Cox proportional hazards, day 60, model 4.
risk of death/hospitalization, 85.2% higher, HR 1.85, p = 0.01, treatment 55 of 2,689 (2.0%), control 32 of 3,331 (1.0%), adjusted per study, inverted to make HR<1 favor treatment, multivariable, Cox proportional hazards, day 28, model 4.
Effect extraction follows pre-specified rules prioritizing more serious outcomes. Submit updates
Zheng et al., 16 Nov 2022, retrospective, United Kingdom, peer-reviewed, mean age 52.0, 33 authors, study period 16 December, 2021 - 10 February, 2022, this trial compares with another treatment - results may be better when compared to placebo.
Contact: laurie.tomlinson@lshtm.ac.uk.
All Studies   All Outcomes   Submit Updates or Corrections
This PaperMolnupiravirAll
Loading..
Please send us corrections, updates, or comments. Vaccines and treatments are complementary. All practical, effective, and safe means should be used based on risk/benefit analysis. No treatment, vaccine, or intervention is 100% available and effective for all current and future variants. We do not provide medical advice. Before taking any medication, consult a qualified physician who can provide personalized advice and details of risks and benefits based on your medical history and situation. FLCCC and WCH provide treatment protocols.
  or use drag and drop   
Submit